SCHEMBL86223

SCHEMBL86223

O=C(O)c1occc(=O)c1OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
GAA P10253 1/20 0.64
MAOB P27338 2/20 0.49
MAOA P21397 1/20 0.48
KCNA2 P16389 1/20 0.46
KCNA5 P22460 1/20 0.46
KCNA1 Q09470 1/20 0.46
POLB P06746 1/20 0.46
KCNA3 P22001 1/20 0.45
NR4A2 P43354 2/20 0.44
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
EDNRA P25101 1/20 0.43
HPGD P15428 2/20 0.43
ALDH1A1 P00352 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SRD5A2 P31213 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14129739 0.88 LMNA (0.61) LMNAGAAMAOBMAOAKCNA2
SCHEMBL4545464 0.86 LMNA (0.62) LMNAGAAMAOBMAOAKCNA2
SCHEMBL13226830 0.85 LMNA (0.60) LMNAGAAMAOBMAOAKCNA2
SCHEMBL19329825 0.84 LMNA (0.56) LMNAGAAMAOBMAOAKCNA2
SCHEMBL4545472 0.84 LMNA (0.63) LMNAGAAMAOBMAOAKCNA2
SCHEMBL10635640 0.83 MRGPRX4 (0.52) LMNAGAAMAOBSMN1; SMN2
SCHEMBL23223241 0.83 LMNA (0.58) LMNAGAAMAOBMAOAKCNA2
SCHEMBL19329810 0.83 LMNA (0.58) LMNAGAAMAOBMAOAKCNA2
SCHEMBL21975951 0.82 LMNA (0.56) LMNAGAAMAOBMAOAKCNA2
SCHEMBL13395926 0.81 GAA (0.52) LMNAGAAMAOBMAOAKCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735055-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS Curasight A/S (DK) 2026-05-06 EP claimed
US-20260077071-A1 Targeted Delivery of Theranostic Agents PETER MACCALLUM CANCER INST (AU) 2026-03-19 US claimed
EP-4448020-B1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS CURASIGHT AS (DK) 2026-02-04 EP claimed
US-20250360218-A1 MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-11-27 US claimed
US-20250049971-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS CURASIGHT A/S (DK) 2025-02-13 US claimed
EP-4493578-A1 TARGETED DELIVERY OF THERANOSTIC AGENTS Peter MacCallum Cancer Institute (AU) 2025-01-22 EP claimed
CN-119272149-A Atmospheric environment monitoring fixed site pollutant monitoring data backtracking method 同济大学 2025-01-07 CN claimed
WO-2025003190-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN BRAIN TUMOURS CURASIGHT A/S (DK) 2025-01-02 WO claimed
EP-4448020-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS Curasight A/S (DK) 2024-10-23 EP claimed
CN-118695877-A Urokinase-type plasminogen activator receptor (UPAR) -PET/CT in neuroendocrine tumors 库拉赛特股份公司 2024-09-24 CN claimed
CN-110128383-B Preparation method of 3- (benzyloxy) -4-oxo-4H-pyran-2-carboxylic acid 南京焕然生物科技有限公司 2022-03-11 CN claimed
CN-112266390-B Preparation method of Barosavir intermediate 南京法恩化学有限公司 2022-03-08 CN claimed
CN-113845502-A Preparation method of 3- (benzyloxy) -4-oxo-4H-pyran-2-carboxylic acid 山东诚创蓝海医药科技有限公司 2021-12-28 CN claimed
CN-112574155-A Synthetic method of 3- (benzyloxy) -4-oxo-4H-pyran-2-carboxylic acid 南京杰运医药科技有限公司 2021-03-30 CN claimed
CN-112266390-A Preparation method of Barosavir intermediate 南京法恩化学有限公司 2021-01-26 CN claimed
WO-2020132820-A1 SYNTHESIS METHOD FOR 3-(BENZYLOXY)-4-OXO-4H-PYRAN-2-CARBOXYLIC ACID 广东莱佛士制药技术有限公司 2020-07-02 WO claimed
CN-210612935-U 3- (benzyloxy) -4-oxo-4H-pyran-2-carboxylic acid apparatus for producing 宁波人健化学制药有限公司 2020-05-26 CN claimed
CN-111018803-A Preparation method of Barosavir intermediate 苏州楚凯药业有限公司 2020-04-17 CN claimed
CN-110128383-A A kind of preparation method of 3- (benzyloxy) -4- oxo -4H- pyrans -2- carboxylic acid 南京焕然生物科技有限公司 2019-08-16 CN claimed
CN-109438405-A A kind of synthetic method of 3- (benzyloxy) -4- oxo -4H- pyrans -2- carboxylic acid 广东莱佛士制药技术有限公司 2019-03-08 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360218-A1 MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION TSPO, TFAM, MCU LMNA 1398/4885GAA 1887/4885MAOB 2896/4885
US-20260077071-A1 Targeted Delivery of Theranostic Agents CCKAR, NPY1R, NPY2R LMNA 1248/4885GAA 1074/4885MAOB 4031/4885
US-20250049971-A1 UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR)-PET/CT IN NEUROENDOCRINE NEOPLAMS PLAUR, PLAU, PROKR1 LMNA 1395/4885GAA 1322/4885MAOB 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.